MAP2K1 and colon carcinoma: In support of this conclusion, another study demonstrated that a MEK1/2 inhibitor PD0325901 was able to suppress the oxaliplatin-induced neuropathy and synergistically potentiated the tumor suppressive effects of oxaliplatin in a colon carcinoma allograft mouse model (Tsubaki et al., 2015).